Stock listing
NASDAQ:BIOS BioPlus Acquisition Corp Stock
Follow BioPlus Acquisition Corp into a list and get an email when it puts out news.
Delisted NASDAQ:BIOS no longer trades. Its last trading date is unknown. Company history and updates stay available on this page.
- Ticker
- NASDAQ:BIOS
- Asset type
- Stock
- Exchange
- NASDAQ
- Currency
- USD
BioPlus Acquisition Corp on 6ix
- Decks
- 3 decks · latest Jun 14, 2023
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (June 2023) | Merger or acquisition | 36 slides | Jun 14, 2023 |
| SPAC Merger (May 2023) | SPAC merger | 36 slides | May 30, 2023 |
| SPAC Merger (May 2023) | SPAC merger | 43 slides | May 3, 2023 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Louis G Lange Other companies: NewAmsterdam Pharma Company N.V. (Director · Since at least Dec 29, 2023); Epiphany Technology Acquisition Corp (Director · Sep 16, 2022 – Sep 16, 2022 · Past); Audentes Therapeutics Inc (Director · Jul 19, 2016 – Jan 15, 2020 · Past); Esperion Therapeutics, Inc. (Director · Jun 25, 2013 – Jul 1, 2013 · Past); Maxygen Inc (Director · May 27, 2010 – Jun 6, 2012 · Past) | Director · Dec 2, 2021 – Dec 2, 2021 · Past |
| Shawn Cross Other companies: Pacira BioSciences, Inc. (Chief Financial Officer · Since at least Oct 21, 2024); Cyclo Therapeutics Inc (Director · Dec 27, 2023 – Feb 27, 2025 · Past); Applied Molecular Transport Inc (CEO & Chair of the Board, Director · Jun 4, 2020 – Dec 27, 2023 · Past); GT Biopharma, Inc. (Chief Executive Officer, Director · Nov 16, 2017 – Nov 16, 2017 · Past) | Director · Dec 2, 2021 – Dec 2, 2021 · Past |
| Jonathan Rigby Other companies: Oncolytics Biotech Inc. (Director · Since at least Jan 1, 2026); SteadyMed Ltd (President and CEO, Director · Dec 28, 2017 – Aug 30, 2018 · Past) | Chief Business Officer, Director · Dec 2, 2021 – Dec 2, 2021 · Past |
| Glen Giovannetti | Director · Dec 2, 2021 – Dec 2, 2021 · Past |
Log in to ask 6ix AI your own questions about BioPlus Acquisition Corp.